EyePoint Pharmaceuticals

Eye Point Pharmaceuticals

Biotechnology, 480 Pleasant St, Watertown, Massachusetts, 02472, United States, 51-200 Employees

eyepointpharma.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is EYEPOINT PHARMACEUTICALS

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorde...

Read More

map
  • 480 Pleasant St, Watertown, Massachusetts, 02472, United States Headquarters: 480 Pleasant St, Watertown, Massachusetts, 02472, United States
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $50 Million to $100 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 3826

checked-icon Does something look wrong? Fix it. | View contact records from EYEPOINT PHARMACEUTICALS

EyePoint Pharmaceuticals Org Chart and Mapping

Employees

Jon Johnson

VP, Market Access Strategy

Richard Plymel

Strategic Account Mamager, East

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding EyePoint Pharmaceuticals

Answer: EyePoint Pharmaceuticals's headquarters are located at 480 Pleasant St, Watertown, Massachusetts, 02472, United States

Answer: EyePoint Pharmaceuticals's phone number is 61********

Answer: EyePoint Pharmaceuticals's official website is https://eyepointpharma.com

Answer: EyePoint Pharmaceuticals's revenue is $50 Million to $100 Million

Answer: EyePoint Pharmaceuticals's SIC: 3826

Answer: EyePoint Pharmaceuticals has 51-200 employees

Answer: EyePoint Pharmaceuticals is in Biotechnology

Answer: EyePoint Pharmaceuticals contact info: Phone number: 61******** Website: https://eyepointpharma.com

Answer: EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Duraserts proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access